- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00301535
A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery
May 15, 2008 updated by: Biopure Corporation
Enhancement of Tissue Preservation During Cardiopulmonary Bypass With HBOC-201 (Registry Study)
The purpose of this study is to determine if Hemopure® will enhance tissue preservation during Cardiopulmonary Bypass surgery.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The primary objective is to determine the safety and feasibility of administering Hemopure® (HBOC-201) to reduce myocardial necrosis, as measured by CK-MB enzyme elevation, and enhance tissue preservation during cardiopulmonary bypass.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tiana Gorham
- Email: tgorham@biopure.com
Study Locations
-
-
-
Thessaloniki, Greece, 552 36
- Recruiting
- Thessaloniki Heart Institute - St. Luke's Hospital
-
Contact:
- Julia Tzelepi, MD
- Email: ktzelepipal@yahoo.gr
-
Principal Investigator:
- Antonis Pitsis, MD
-
-
-
-
-
Johannesburg, South Africa
- Recruiting
- Milpark Hospital
-
Contact:
- Ronel Snyman
- Email: research.jhb@mweb.co.za
-
Principal Investigator:
- Martin Sussman, MD
-
Sub-Investigator:
- Christopher A Hammond, MD
-
-
-
-
Oxfordshire
-
Headington, Oxfordshire, United Kingdom, OX3 9DU
- Recruiting
- Oxford Heart Centre - John Radcliffe Hospital
-
Principal Investigator:
- Stephen Westaby, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is between the ages of 18 and 80.
- Subject is an acceptable candidate for CABG.
- Subject is scheduled for CABG (without planned valvular repair or replacement) by cardiopulmonary bypass.
- Subject signs informed consent
- Subject and the treating physician agree that subject can comply with all study procedures and follow-up visit at time of subject screening.
Exclusion Criteria:
- Pre-operative myocardial infarction, defined as CK-MB level > 2 times upper limit of normal 24 hours prior to CABG surgery.
- Renal failure defined as serum creatinine greater 220 µmol/L
- Subject has an ejection fraction ≤ 30% (as measured by Echocardiography within 30 days of study enrollment).
- Active infection.
- History of prior stroke within last six months or history of prior stroke with residual neurological deficit.
- Transient Ischemic attack within last 6 months.
- Subject has a history of coagulopathy.
- Subject is pregnant or currently breastfeeding.
- History of allergy to beef products.
- Pre-operative cardiogenic shock defined as cardiac index ≤ 1.8.L/min/m2 despite the use of vasopressors.
- Underlying medical conditions that would limit subject's life expectancy to less than 12 months.
- Severe pulmonary disease [based upon clinical diagnosis or pulmonary function tests (FEV <1 liter), if available] that may interfere with weaning subject from ventilator.
- History of acute central nervous disorder (e.g., seizure or traumatic injury).
- Severe hypertension (≥ 160/90 mm Hg) that cannot be medically controlled despite treatment with two antihypertensive therapies.
- Severe liver dysfunction as defined by total bilirubin ≥ 51 µmol/L or 2 times the site normal limit of AST or ALT activity.
- Subject has systemic mastocytosis.
- Subject has any condition that predisposes the subject to systemic mast cell degranulation or hypersensitivity reactions or a history of severe allergic reactions to drugs or environmental allergens.
- Subject has participated in another investigational drug, biologic or device study within 30 days prior to study enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
|
No Intervention: 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of peak CK-MB elevation ≥ 5X upper limit of normal
Time Frame: Baseline; Peri-op; Days 1,2,3 post procedure; Discharge or Day 6 post procedure(whichever is earlier)
|
Baseline; Peri-op; Days 1,2,3 post procedure; Discharge or Day 6 post procedure(whichever is earlier)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MACE @ discharge and 30 days post surgery; Change in renal function; Renal failure; Increased Cardiac Troponin T; Death rate; MI/stroke; Supplemental RBC transfusions; Total units RBC and HBOC-201; Intra Aortic Balloon Pump use, pump time; New onset CHF
Time Frame: Duration of the study
|
Duration of the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: A. Gerson Greenburg, MD, Ph.D, Biopure Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (Anticipated)
July 1, 2008
Study Completion (Anticipated)
September 1, 2008
Study Registration Dates
First Submitted
March 9, 2006
First Submitted That Met QC Criteria
March 10, 2006
First Posted (Estimate)
March 13, 2006
Study Record Updates
Last Update Posted (Estimate)
May 16, 2008
Last Update Submitted That Met QC Criteria
May 15, 2008
Last Verified
May 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Blood Substitutes
- Chrysarobin
- HBOC 201
Other Study ID Numbers
- BIOEU003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on HBOC-201 (hemoglobin glutamer-250 bovine)
-
Mauricio LynnAvailable
-
Jonathan H. WatersHbO2 Therapeutics LLCAvailableAnemia SevereUnited States
-
Biopure CorporationTerminatedPeripheral Vascular DiseaseUnited Kingdom, South Africa
-
Biopure CorporationCompletedMyocardial Infarction | Angina Pectoris | Unstable AnginaBelgium, Germany, Netherlands
-
Biopure CorporationCompletedAcute Coronary Syndrome | Coronary OcclusionNetherlands
-
Biopure CorporationUnknownWounds and InjuriesSouth Africa